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T
he prevalence of obesity appears to
have reached a plateau in the U.S.
between 2003 and 2007 (1), but the
obesity epidemic is still rampant in many
other countries—especially in the devel-
opingworld(2)—inadultsaswellaschil-
dren (http://www.who.int/topics/obesity/
en/). A recent analysis of a large
prospective cohort of individuals 50–71
yearsold(3)hasgeneratedaprecisedose-
response gradient for the positive associ-
ation of BMI and relative risk of death
independent of other risk factors (espe-
cially smoking and preexisting disease,
which cause weight loss). Yet, long-term
observational studies have generally
found that weight loss, whether sponta-
neous or intentional, is associated with
increased, rather than decreased, overall
mortality (rev. in 4).
Lifestyle intervention (diet and exer-
cise), behavioral management, and drug
therapy for obesity deliver a degree of
weight loss that is usually modest (and
therefore unattractive to patients) and
short-lived (6 months to 1 year at best)
and carry considerable side effects. More-
over, despite the attenuation of risk fac-
tors such as diabetes and dyslipidemia,
trialevidenceforaneffectoftheseweight-
control approaches on reducing cardio-
vascular disease or mortality is still
lacking(rev.in5).Ontheotherhand,and
perhaps as a consequence, surgery for the
treatment of severe obesity is gaining in-
creasingfavor.TheannualU.S.frequency
of hospital discharges that included bari-
atric surgery increased sevenfold (from
3.5 to 24.0 per 100,000) between 1996
and 2002 (6). According to a review of
85,048 morbidly obese patients (7), early
(30 days) and late (30 days to 2 years)
mortality rates for bariatric surgery trend
downward (0.28 and 0.35%, respec-
tively).Surgicaltreatmentofmassiveobe-
sity is being extended to adolescents,
seemingly with similar success and risk
rates as in adults (8–10). Recently, the
10.9-yearfollow-upoftheSwedishObese
SubjectsStudyreporteda30%riskreduc-
tion for overall mortality in 2,010 obese
patients who had undergone bariatric
surgery (11). Likewise, in a retrospective
cohort of 7,925 surgical patients (12),
mortality from any cause was 40% lower
than in 7,925 nonsurgical obese patients.
These ﬁndings are striking, particu-
larly when considering the high rate of
failureofothertreatmentmodalities,such
as caloric restriction (13) and antiobesity
drugs(14),andmayfosterachangeinthe
indications for bariatric surgery (15).
They also raise a number of questions.
The question we address here is the im-
pact of bariatric surgery on type 2 diabe-
tes, its size, and mechanisms.
Bariatric surgery and type 2 diabetes
A systematic review and meta-analysis of
the English literature including 22,000
patients (73% women, mean BMI 47 kg/
m
2) reported complete resolution of type
2 diabetes (deﬁned as discontinuation of
all diabetes-related medications and
blood glucose levels within the normal
range) in 77% of cases. This percentage
increased to 85% when counting patients
reporting improvement of glycemic con-
trol, and diabetes resolution occurred in
concomitancewithanaverageweightloss
of 41 kg (65% of the excess weight)
(16). In the analysis by Adams et al. (12),
deaths attributed to diabetes were re-
ducedbyaphenomenal92%.Thus,there
can be little doubt that in very obese pa-
tients with type 2 diabetes bariatric sur-
gery in general is a highly effective means
of curing type 2 diabetes. However, the
mostfrequentkindoftype2diabetes,i.e.,
the hyperglycemia surfacing after the
fourth decade of life in moderately obese
subjects, is a progressive disease (17) that
rarely undergoes resolution, whether
spontaneously or with treatment. One
possibility is that the hyperglycemia of
morbid obesity (BMI between 35 and 70
kg/m
2) has a pathogenesis different from
that of the hyperglycemia of moderately
obese (BMI between 27 and 34 kg/m
2)o r
leantype2diabetes.Anotherpossibilityis
that bariatric surgery per se interferes
with glucose metabolism in ways that
none of the other antidiabetes treatments
do. Because circulating glucose levels
quantitatively result from the insulin sen-
sitivity of glucose uptake (in peripheral
tissues) or release (by the liver) and the
dynamics (amount and time course) of
insulinmadeavailableby-cells,weshall
ﬁrst review the evidence linking sur-
gery-induced weight loss with changes in
insulin sensitivity and -cell function.
Next, other potential interactions will be
discussed.
Bariatric operations
A number of surgical approaches to in-
duce weight loss have been developed,
and several are in current use (cf. ref. 18
for a detailed description). In general,
they can be grouped into purely restric-
tive,mostlyrestrictive,andmostlymalab-
sorptive procedures. In the ﬁrst group,
the most common procedure is laparo-
scopicadjustablegastricbanding(LAGB),
which consists of placing a band around
the upper part of the stomach, thereby
creating a small pouch that empties into
the lower stomach without bypassing the
foregut (see Figure A1 in the online ap-
pendix available at http://dx.doi.org/10.
2337/dc08-1762). In the cited meta-
analysis (16), LAGB was associated with
the loss of 32–70% of excess weight. Ver-
tical banded gastroplasty is a variant of
LAGB, typically leading to the loss of 48–
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techniques, the mechanism essentially
hinges upon generating effective satiety
signals for small amounts of ingested
food.
Probably the most common weight-
loss surgery is the Roux-en-Y gastric by-
pass (RYGB), in which the stomach is
reducedtoasmallpouch(30ml)thatis
connectedviaatightoutlettothejejunum
just past the duodenum while the jejunal
stump is anastomosed to the lower jeju-
num in a Y conformation (Fig. 1). Here, a
degree of gastric restriction comparable
with that of LAGB (but not adjustable) is
coupledwiththebypassoftheduodenum
and upper jejunum, making RYGB a
mostly restrictive procedure. Between 33
and 77% of excess weight can be lost fol-
lowing RYGB (16).
With the jejunoileal bypass, the gas-
tric content is emptied directly into the
terminal ileum, thereby inducing major
malabsorption with no restriction of food
intake. Now abandoned, this procedure
led to the development of current malab-
sorptive approaches, the prototype of
which is biliopancreatic diversion (BPD).
Here, a 60% distal gastric resection with
stapled closure of the duodenal stump re-
sults in a residual stomach volume of
300 ml. The small bowel is transected
2.5 m from the ileocecal valve, and its
distal end is anastomosed to the remain-
ing stomach. The proximal end of the il-
eum, comprising the remaining small
bowel carrying the biliopancreatic juice
and excluded from food transit, is anasto-
mosedtothebowel50cmproximaltothe
ileocecal valve. Consequently, the total
length of absorbing bowel is 250 cm, the
ﬁnal 50 cm of which represents the site
where ingested food and biliopancreatic
juices mix (Fig. 1). This mostly malab-
sorptive approach is associated with the
highest (62–75%) (16) and most durable
(19) degree of excess weight loss.
Weight loss and insulin sensitivity:
preliminary considerations
Adiposity is one of the physiological de-
terminants of insulin sensitivity (20).
Weight loss has been shown to enhance
insulinsensitivityunderallcircumstances
(rev. in 21) except wasting, major stress,
and HIV infection (22–24). Surgically in-
duced weight loss, in general, appears to
take no exception (see below). However,
selective surgical removal of fat tissue
from subcutaneous depots does not
improve insulin resistance. In a well-
controlled study of 15 obese women (7 of
whom had diabetes), removal of 9–10 kg
of subcutaneous abdominal fat by lipo-
suction did not change insulin-mediated
glucose disposal (on a euglycemic-
hyperinsulinemic clamp) despite the ex-
pected drop in circulating leptin levels
(25). Although other studies using lipo-
suctionhavereportedsomeimprovement
of insulin sensitivity in the longer term
(26), this observation clearly implies that
factors other than the sheer mass of sub-
cutaneous adipose tissue have an impact
on insulin action. Thus, large adipocytes,
such as those that are deposited in subcu-
taneous depots during weight gain, are
less sensitive to insulin than small adipo-
cytes (27); their degree of insulin unre-
sponsiveness in vitro correlates with in
vivoinsulininsensitivity(28).Ectopicfat,
accumulated in abdominal visceral de-
pots, skeletal muscle, and liver, has been
speciﬁcally linked with the presence of
insulin resistance independently of total
adiposity. In support of these ﬁndings,
surgical removal of visceral, but not sub-
cutaneous, fat from aging or diabetic rats
restores insulin sensitivity and glucose
tolerance(29).Inobesehumans,themet-
abolic changes induced by weight loss,
i.e., insulin sensitization of both glucose
metabolism and lipolysis, have been re-
lated to the depletion of ectopic fat stores
(30–35).Importantly,whereasfastingfor
3 days depresses insulin action in obese
subjects (36), caloric restriction enhances
it(37),accountingforasmuchincreasein
insulin sensitivity as weight loss itself
(38). Finally, several peptides expressed
and released by adipose tissue are meta-
bolicallyactive.Forexample,adiponectin
upregulates insulin action in liver and
skeletal muscle, whereas high circulating
levels of some adipocytokines (e.g., tu-
mor necrosis factor- and retinol binding
protein 4) correlate with in vivo insulin
resistance (39).
Collectively, these observations sug-
gest the following considerations when
interpreting the evidence linking surgi-
cally induced weight loss (or, for that
matter, any weight change) and insulin
sensitivity:
● quality and site are as important as
amount of fat gained or lost;
● energybalancematterstoinsulinaction
independently of weight changes;
● the endocrine activity of adipose tissue
itself may interfere with the relation-
ship between changes in adiposity and
insulin sensitivity;
● coordinate changes in body weight and
insulin sensitivity may differ between
diabetic and nondiabetic subjects;
● metabolic abnormalities may emerge at
different BMI thresholds in individuals
of diverse ethnic background (40);
● speciﬁcally for bariatric surgery, an un-
derstanding of how gastrointestinal
transit is altered by the operation may
be key to interpreting metabolic effects
for any given amount of weight loss.
Bariatric surgery and insulin
sensitivity: results
Online appendix Table A1 lists the stud-
ies in which data on insulin sensitivity
have been reported for obese type 2 dia-
betic patients undergoing bariatric sur-
gery. With the proviso that our literature
search has likely missed diabetic patients
included in series that did not provide re-
sults separately for diabetic and nondia-
betic subjects, the studies in online
appendix Table A1 include 450 type 2
diabeticpatientsreportedoveraperiodof
25 years. As can be appreciated, type of
surgery,durationoffollow-up,andmeth-
odology vary enough to preclude precise
quantitation of the impact of weight loss
on insulin sensitivity. Nevertheless, some
information can be derived from these
data (with no pretense of bona ﬁde meta-
analysis). Thus, the weighted mean of
preoperative BMI in all 423 patients was
46.4 kg/m
2, which reﬂects the current in-
dications for bariatric surgery (BMI 40
kg/m
2 or 35 kg/m
2 in complicated obe-
sity). In the 204 patients in whom ho-
meostasis model assessment (HOMA)
(HOMA of insulin resistance, in this case)
was used to assess changes in insulin
sensitivity 4 months after surgery
(weighted mean 12 months), insulin sen-
sitivity improved by 51% for a mean BMI
drop of 32% (40 kg). The percent
changesinBMIandHOMAacrossthedif-
ferent studies were loosely related to one
another. In the 79 patients in whom
HOMA was measured 4 months after
surgery (weighted mean 1.5 months), in-
sulin sensitivity improved by 49% for a
BMI decrease of 10% (with no correlation
between the respective decrements). The
few studies in online appendix Table A1
using different methods of estimating in-
sulin sensitivity (insulin sensitivity test,
insulin tolerance test, frequently sampled
intravenous glucose tolerance test, and
clamp [60–65]) do not in general run
contrary to this result. Therefore, with all
the approximations of this sort of analy-
sis, the notions emerge that 1) bariatric
surgery is capable of improving the insu-
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while at the same time causing a 30%
decrease in BMI and 2) this improvement
of insulin sensitivity may be seen already
6 weeks following surgery, at which
time BMI may be decreased by only 11%.
The latter apparent paradox may result
from the use of surrogate measures of in-
sulin sensitivity (HOMA). It can also be at
leastpartlyexplainedbythefactthatearly
after surgery, caloric restriction per se
(whether achieved by lower intake as per
restrictive procedures or reduced absorp-
tion as with malabsorptive operations)
plays a major role in improving insulin
action. Months to years after surgery,
weight loss has generally leveled off; a
quantitative relationship between the
changes in BMI and insulin sensitivity is
now usually evident. The weakness of the
correlationbetweenthelossofweightand
the gain in insulin sensitivity has been re-
peatedlynoted.Forexample,inanonran-
domized study comparing LAGB and
RYGB in a large number of nondiabetic
patients (66), HOMA at 30 months post-
surgery was similar but RYGB induced a
signiﬁcantlylargerweightlossthanLAGB
(33vs.22%).Itshouldbeconsidered
that, in addition to the confounding fac-
torsmentionedintheprevioussection,an
important determinant of weight loss is
the initial body weight. For example, in a
prospective 2-year follow-up of 107 men
and women undergoing BPD at one cen-
ter, there was a strong correlation (r 
0.68)betweeninitialweightandachieved
weight loss, which was entirely driven by
initial fat mass (r  0.64) and not fat-free
mass (FFM) (67). This phenomenon is
reminiscent of the common clinical ob-
servation that with any treatment the re-
sponseisproportionaltotheinitialheight
of the abnormality (e.g., A1C or arterial
blood pressure). As with these other vari-
ables, the biology underlying this appar-
ent rule is unclear.
The questions now arise 1) whether
insulin sensitivity is fully restored despite
the fact that postoperative BMI typically
remains in the obese range, 2) whether
the heightened insulin sensitivity is alone
responsible for the resolution/improve-
ment of hyperglycemia, and 3) whether
the different surgical approaches differ
from one another in their insulin-sen-
sitizing power.
Some relevant information can be de-
rived from the few studies that have em-
ployed the clamp technique to directly
measure insulin sensitivity. In two differ-
ent databases using the same exogenous
insulin infusion rate, the dependency of
whole-body insulin sensitivity on BMI is
best described by curvilinear ﬁts (online
appendix Fig. A2). Both in the European
Group for the Study of Insulin Resistance
(EGIR) cohort (20) and in the study by
Muscelli et al. (68), a 30% reduction in
BMI (from 46 kg/m
2) predicts a 50% in-
crease in insulin sensitivity. However,
both interpolating functions also predict
that insulin sensitivity would not be fully
restored by a 30% weight decrement (to
the level of 42 mol   kgFFM
1   min
1
associated with a BMI of 25 kg/m
2).
We then used these cross-sectional
relationshipstoscaletheresultsofinsulin
clampstudiesinsubjectslosingweightby
different approaches. In nondiabetic sub-
jects on a calorie-restricted diet (69) or
undergoing RYGB (68), the data fall well
within the 95% CIs of the ﬁt (Fig. 1)—in
other words, when weight-stabilized sub-
jects had gained insulin sensitivity in ex-
act proportion to the weight change.
Strikingly similar results are obtained
when plotting data from two other clamp
studies, using caloric restriction (38) or
RYGB (70). In contrast, in 107 patients,
35 of whom with type 2 diabetes, under-
goingBPDandrestudied2yearslater,the
increase in insulin sensitivity deﬁnitely
exceeded the prediction; i.e., insulin re-
sistance was normal or supernormal at
BMI values still in the obese range (67).
Furthermore, in one study (71) where in-
sulin sensitivity was estimated at variable
(but not sequential) time intervals follow-
ing BPD, completely normal rates of
insulin-mediated glucose clearance were
found as early as 10 days after surgery; at
this time, marked insulin resistance was
present in a control group of morbidly
obese patients undergoing major non-
bariatric abdominal surgery.
With regard to hepatic insulin resis-
tance, we could ﬁnd no study that mea-
sured endogenous glucose production in
obese diabetic patients before and after
surgery. However, given that hepatic and
peripheral insulin resistance correlate
witheachother,thepatternofresultsout-
linedforinsulin-mediatedglucoseuptake
canprobablybeextrapolatedtotheeffects
of insulin on endogenous (hepatic) insu-
lin sensitivity. As for fat distribution, in a
large cohort of subjects (including type 2
diabetic patients) undergoing LAGB, the
ratio of visceral to subcutaneous abdom-
inalfat(measuredbyultrasound)wassig-
niﬁcantly reduced 1 year postoperatively
in concomitance with a weight loss of 8
BMI units (43). This ﬁnding is consistent
with the notion that fat is more rapidly
lost from visceral than subcutaneous de-
pots. Whereas this fat redistribution may
contribute to the improvement of other
metabolic abnormalities, it is doubtful
that selective fat removal in very obese
subjects who lose substantial portions of
excess weight affects insulin action over
and above what is engendered by weight
loss itself.
Patients with diabetes appear to lose
signiﬁcantly less weight than equally
obese nondiabetic subjects following gas-
tric bypass (72). Whether the gain in in-
sulin sensitivity in obese type 2 diabetic
patients is any different from that of the
nondiabetic obese individuals for the
same weight reduction has not been ex-
amined systematically. In one series (71),
insulin sensitivity was fully restored in
subjects with normal glucose tolerance,
impaired glucose tolerance, or type 2 di-
Figure 1—The results (symbols) are means 	 SEM in patients undergoing weight loss by diet
(ref. 69), RYGB, or BPD (ref. 68). Green arrows connect pretreatment to posttreatment values.
The black line and the black dots are the ﬁtting function and 95% CIs of the data in ref. 68 (same
as in online appendix Fig. A2, bottom graph). FFM, fat-free mass; T2DM, type 2 diabetes.
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abetic patients had lower presurgery
levels of insulin sensitivity, their gain was
the highest.
The picture emerging from this anal-
ysisisasfollows:Surgicalproceduresthat
greatly restrain food intake (RYGB) or ab-
sorption (BPD) may induce some recov-
ery of insulin sensitivity before any large
weight loss has occurred. However, when
tested under conditions of stable energy
balance, insulin resistance is increased by
surgically induced weight loss quantita-
tively. Therefore, long-term–postsurgery
morbidlyobesepatients(nondiabeticand
diabetic alike) are likely to retain a degree
of insulin resistance if their BMI is still in
the overweight/obese range. Malabsorp-
tive procedures take exception in that
they may improve insulin sensitivity be-
yondtheeffectofweightloss.Thisfunda-
mental difference between mainly
restrictive and malabsorptive procedures
needs to be proven by prospective, ran-
domized studies.
Bariatric surgery and -cell function
Assessing -cell function is problematic
becausecurrentlynoclinicaltesthasbeen
agreeduponasbeingthegoldstandardin
the way that the clamp has for the mea-
surement of insulin sensitivity. Further-
more, insulin secretion is intrinsically
complex because -cells must adapt to
chronic stimuli (e.g., weight changes) as
well as respond to acute challenges (i.e.,
thesuccessionoffastingandfeeding).For
the sake of the following discussion, it is
important to distinguish between secre-
tory indexes that reﬂect long-term adap-
tation from those that result from the
dynamic behavior of the -cell. Basal in-
sulin secretion and total insulin output in
response to a standard stimulus are set
points ofsecretory capacity, whereas -cell
glucose sensitivity (or the slope of the insu-
lin secretion/plasma glucose dose-response
relationship) is the ability to control glyce-
mia by promptly releasing sufﬁcient hor-
mone. This key function is reﬂected in
empirical indexes such as the acute insulin
response (AIR) to intravenous glucose or
the insulinogenic index on the oral glucose
tolerance test or a mixed meal.
Data on changes in -cell function
with bariatric surgery are few but rela-
tively consistent. Fasting insulin concen-
trations (44,51) or secretion rates (54)
and total insulin output in response to
intravenous (47) or oral glucose (71) or
mixed meals (54) all have been found to
decrease after any bariatric procedure.
This is the expected consequence of the
reduced adipose mass and improved in-
sulin sensitivity (73). In contrast, in type
2 diabetic patients, HOMA of -cell func-
tion after LAGB (45), AIR and the insuli-
nogenic index after RYGB (49,52), and
AIR after BPD (47) all increased to a vari-
able extent. Model-derived -cell glucose
sensitivitywasfullynormalizedin10type
2 diabetic patients 2 years post-BPD in
parallelwiththenormalizationofdaylong
plasma glucose concentrations (54).
Thus, surgical weight loss generally
lowers the set point but heightens the dy-
namic responsivity of the-cell. Whether
-cellfunctionisfullyrestoredappearsto
depend principally on the severity of dia-
betes (relative to duration, degree of met-
abolic control, and intensity of anti-
diabetes treatment) (45,55). With purely
or mostly restrictive procedures, -cell
function shows progressive improvement
over time, paralleling ongoing weight
loss.WithBPD,almostcompleterecovery
of AIR has been reported in a small group
of type 2 diabetic patients as early as 1
month postsurgery (59).
All in all, diabetes in the very obese
does not appear to differ in pathophysiol-
ogy from the more common variety of
moderately obese diabetes. Clearly, insu-
lin resistance is more severe because of its
quantitative relation to BMI, and drastic
increments in insulin action with major
weight loss underlie the spectacular re-
mission rates. -Cell function recovers
in large part or in full probably depend-
ing on its initial, genetically determined
quality.
Mechanisms
Food intake, transit, and absorption are
regulated by a complex network includ-
ing the gastrointestinal system, the liver,
andthebrain(rev.in74).Surgicalrestric-
tion of the stomach may change circulat-
ing concentrations of ghrelin, a hormone
secreted by endocrine cells in the fundus.
When infused into healthy volunteers,
ghrelin induces acute insulin resistance
(75). However, changes in ghrelin levels
afterbariatricsurgeryhavebeeninconsis-
tentandunrelatedtotheensuingchanges
in insulin sensitivity (76). Changes in
other gastrointestinal hormones have
been analyzed for those bariatric proce-
dures that alter food transit. Glucagon-
likepeptide-1(GLP-1)potentiatesinsulin
release in a glucose-dependent manner
(74). GLP-1 responses (to glucose or
mixed meals) are impaired in association
with both type 2 diabetes and obesity
(77), and GLP-1 levels increase early after
both RYGB (58,78) and BPD (53) but ap-
parently not after diet (58). Thus, one
possibilityisthatheightenedGLP-1levels
contribute to the improvement in -cell
function detectable early after surgery. It
isnotclearwhattheprecisemechanismis
by which GLP-1 release is revved up by
anatomicalrearrangementsthateitherby-
pass the duodenum and upper jejunum
(RYGB) or exclude the larger part of the
entire gastrointestinal tract from food
transit (BPD). However, in one study,
GLP-1 at 6 weeks postsurgery was in-
creased in normotolerant and impaired
glucose-tolerantsubjectsbutnotintype2
diabetic patients despite similar improve-
mentsininsulinresistanceand-celldys-
function (49). Also, infusion of GLP-1 to
pharmacological levels fails to stimulate
insulin-mediated glucose disposal in
healthy volunteers or under experimental
conditions where its effects on endoge-
nous insulin release are prevented (as in
type1diabeticpatients)(rev.in79).Cou-
pled with the current notion that GLP-1
receptors have not been demonstrated in
liver, skeletal muscle, or adipose tissue,
one can conclude that GLP-1 is an un-
likely candidate to explain the remission
of insulin resistance in bariatric patients.
The involvement of glucose-dependent
insulinotropic polypeptide (GIP) is even
less clear. GIP resistance has been repeat-
edlydescribedintype2diabetes(e.g.,ref.
77), and GIP knockout in mice improves
insulin action (80). However, following
RYGB, increased (58) or unchanged (81)
GIP levels have been reported in type 2
diabetic patients. On the other hand,
GLP-1 has been implicated in the dump-
ingsyndromeandthereactivehypoglyce-
mia that may follow gastric surgery (82).
Its trophic actions on -cells have been
called upon to explain six cases of histo-
logically proven nesidioblastosis after
RYGB (83).
Further involvement of the gastroin-
testinal tract has been inferred from the
outcome of novel surgical approaches. In
Goto-Kakizaki rats, Rubino et al. (84)
found that excluding a short segment of
proximal intestine from food passage (via
aduodenal-jejunalbypassoragastrojeju-
nostomy) improved glucose tolerance,
whereas restoring duodenal transit rees-
tablished glucose intolerance. This obser-
vation has led to a foregut hypothesis,
which holds that contact of nutrients
with the duodenal mucosa generates
signals(hormonaland/orneural)thatin-
terferewithglucosemetabolismandinsu-
Ferrannini and Mingrone
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(as in RYGB and BPD) would remove this
inhibition.
In the rat, Strader et al. (85) showed
that effects similar to those of duodenal
exclusioncouldbeproducedbytranspos-
ing an ileal segment into the upper intes-
tine. In studies in type 2 diabetic patients
with a BMI 35 kg/m
2, DePaula et al.
(86) reported that ileal interposition with
a sleeve gastrectomy (with or without di-
version) resulted in weight loss and a
drastic fall in A1C, fasting glucose, and
HOMA-IR 7 months later. A “hindgut hy-
pothesis” thus proposes that contact with
undigested nutrients triggers an ileal
brake, i.e., a combination of effects inﬂu-
encing eating behavior and digestion.
Finally, in rats, diversion of the bile
ﬂow from the duodenum into the second
jejunal loop leads to improved tolerance
to oral as well as intravenous glucose
compared with sham-operated animals
(87). BPD is the only bariatric approach
that causes major lipid malabsorption at
the same time as it depletes intramyocel-
lular lipids and returns insulin sensitivity
to normal or supranormal levels in the
longer term (88). Fat starvation in rats re-
produces the metabolic picture of BPD
with surprising precision (89). Therefore,
lipids and lipid signal molecules—and
their control by the bile—must be among
key messengers released by a subverted
gastrointestinal tract.
CONCLUSIONS — Bariatric surgery
is a highly effective means of inducing di-
abetes remission in very obese patients
with type 2 diabetes. Rank order of in-
creasingefﬁcacyofthemostcommonsur-
gical procedures progresses from the
purely restrictive to the mostly restrictive
to the mostly malabsorptive; several new
approaches, however, are under very ac-
tive investigation. Diabetes remission re-
sults from the joint improvement of
insulin resistance and -cell dysfunction.
Better insulin action on glucose metabo-
lism relieves secretory pressure on the
-cell, resulting in reduced insulin out-
put; dynamic -cell responses, however,
are restored. Rates of complete diabetes
remission or glycemic improvement de-
pend essentially on the severity of diabe-
tes (as indexed by duration, A1C levels,
presence of complications, and intensity
of treatment). Factors such as family his-
tory, interaction with previous anti-
diabetes therapies, or evidence of auto-
immunity have not been analyzed
speciﬁcally.
Caloricrestrictionandweightlossare
the dominant mechanisms of improved
glucose metabolism. The former appears
to account for the early postsurgical re-
covery of insulin sensitivity and secretory
dynamics; the latter is the ﬁnal determi-
nant of the outcome once weight and ca-
loric balance have stabilized. When food
transit is surgically altered, changes in the
pattern of gastrointestinal hormone re-
lease may support the early adaptation of
-cell function but are unlikely to make a
major contribution to insulin action.
Whether bariatric operations exert an
intrinsic antidiabetes action beyond
weightlossremainsunproven.Thebestof
available evidence indicates that malab-
sorptive operations presently offer the
highest chances of revealing weight-
independent mechanisms of diabetes res-
olution, but smart manipulations of food
passage may open entirely new avenues.
Experimenting in less obese or nonobese
diabetes or minimizing weight loss may
providefurtherevidence.Difﬁcultasthey
may be, randomized controlled clinical
studies using state-of-the-art methodol-
ogy are required to prove the worth of
metabolic surgery.
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